Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04053803 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia
A Phase 2 study of Sickle Cell Disease, sponsored by Imara.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 7
- Study locations
NCT04053803: Active Phase 2 study of Sickle Cell Disease, sponsored by Imara.
NCT04053803 is a Phase 2 study of Sickle Cell Disease that is active but no longer recruiting, run by Imara. The registered enrollment target is 30 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04053803, a Phase 2 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by Imara.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.
Primary Outcome
1. Incidence of Adverse Events 2. Incidence of Serious Adverse Events
Conditions Studied
Interventions
- DRUG IMR-687
Study Locations (7)
Other
- Bristol Haematology and Oncology Centre - Bristol
- University College London Hospital NHS Foundation Trust - London
- Guy's and St Thomas Hospital CRF - London
- Royal London Hospital - London
Connecticut
- University of Connecticut Health Center - Farmington
Florida
- Foundation for Sickle Cell Disease Research - Hollywood
Texas
- Baylor Scott & White Medical Center - Temple - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2025-03 |
| Phase | Phase 2 |
What the registry record for NCT04053803 still lists
NCT04053803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which IMR-687 is the first listed.
NCT04053803 lists 7 locations in 4 states (Other, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT04053803 about?
NCT04053803 is a clinical study titled "An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia". This is an open-label extension study of IMR-687 in adult patients who completed Imara's blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term safety and tolerability.
What is the current status of trial NCT04053803?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-05-22. Estimated completion is 2025-03.
What conditions does trial NCT04053803 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT04053803?
The interventions under investigation include: IMR-687 (DRUG).
Who is sponsoring clinical trial NCT04053803?
This trial is sponsored by Imara, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04053803 being conducted?
This trial has 7 study locations across Connecticut, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04053803's enrollment target sits among peer trials
30 139th of 213 higher than 67 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI